Tango Therapeutics (NASDAQ: TNGX) revenue
Tango Therapeutics reported revenue of $62.4m for fiscal 2025, 48.3% more than in fiscal 2024 ($42.1m). Since fiscal 2020 its revenue has grown by 714.8%, an average growth of 52.1% a year.
Tango Therapeutics has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record. The biggest drop was in fiscal 2022, −32.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $62.4m | +48.3% | −$111.3m | −178.4% |
| 2024 | $42.1m | +15.2% | −$145.6m | −346.1% |
| 2023 | $36.5m | +46.9% | −$114.2m | −312.6% |
| 2022 | $24.9m | −32.9% | −$111.1m | −446.8% |
| 2021 | $37.0m | +383.8% | −$58.2m | −157.1% |
| 2020 | $7.7m | — | −$52.2m | −681.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Tango Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Tango Therapeutics ranks 320th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Tango Therapeutics, 48.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 318th | Enanta Pharmaceuticals | $65.3m | −3.4% |
| 319th | Nuvation Bio | $62.9m | 699.0% |
| 320th | Tango Therapeutics | $62.4m | 48.3% |
| 321st | CVRX | $56.7m | 10.4% |
| 322nd | 908 Devices | $56.2m | 17.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Tango Therapeutics
- How much revenue did Tango Therapeutics make in fiscal 2025?
- Tango Therapeutics reported revenue of $62.4m for fiscal 2025, compared with $42.1m in fiscal 2024.
- How much has the revenue of Tango Therapeutics grown?
- Between fiscal 2020 and fiscal 2025 it went from $7.7m to $62.4m: 714.8% more, an average growth of 52.1% a year.
- What was the best year for revenue at Tango Therapeutics?
- Of its last 6 fiscal years, fiscal 2025, with $62.4m.
- Where does Tango Therapeutics rank in its sector by revenue?
- It ranks 320th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Tango Therapeutics come from?
- From the annual report (Form 10-K) that Tango Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Tango Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Tango Therapeutics: the Tango Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.